Total Funding
86
74
Total FundingSeed raised
Growth Score 86 in past quarter
-4 pts
Heat Score 74 in past quarter
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
56038
Exin Therapeutics offers next-gen neurotherapeutics leverage machine learning, genome editing, & bioelectronic medicine.
- Ivan Lazarte: Co-founder and CSO
- Gabriel Ocana Santero: Co-founder and CEO
About the Company
Exin Therapeutics is developing a discovery platform for next-generation genetic therapies targeting dysregulated neural circuits across disorders, and next-generation neurotherapeutics leverage advancements in genetics, technology, and engineering to create innovative treatments for neurological disorders. These therapies, which include gene
therapy, nucleotide-based therapeutics, and cell-based therapies, address previously untreatable disease mechanisms and unmet medical needs.